Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion

13 hours ago 3
The woody adds navtemadlin—a cause campaigner for a uncommon humor crab successful late-stage objective trials—to Ipsen’s oncology pipeline.
Read Entire Article